Skip to main content
. 2022 Feb 14;9(1):39–49. doi: 10.36469/jheor.2022.31825

Figure 3. Comparison of Patients Having Any, ≥5%, Or ≥10% Weight or BMI Increases Between Pre-index and Post-index Periods.

Figure 3.

* P value significant at the 5% level.

Abbreviations: BMI, body mass index; CI, confidence interval; OR, odds ratio; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate.

a ORs and their associated 95% CIs and P values were estimated using logistic regression models adjusted for the following baseline characteristics: age, gender, race, insurance plan type, US geographic region, year of the index date, number of mental health–related comorbidities, symptomatic HIV/AIDS, Quan-Charlson Comorbidity Index score, hypertension, type 2 diabetes, prediabetes, baseline BMI, use of an INSTI agent in the index regimen, and use of a medication associated with weight change. An OR <1 indicates that the TAF 10 mg, TDF, or non-TAF/TDF cohorts had a lower risk of a weight gain or BMI increase than the TAF 25 mg cohort.